We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Ethiopian Ministry of Health has reported that 35,000 people living with AIDS have begun taking antiretroviral (ARV) drugs as provided by governmental and private hospitals.
Health Canada has approved Rituxan (rituximab) in combination with methotrexate to reduce signs and symptoms in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) inhibitor therapies.
Swiss drugmaker Roche has announced that MabThera (rituximab) has received a recommendation for approval from the Committee for Medicinal Products for Human Use (CHMP) for the treatment of rheumatoid arthritis (RA) in Europe.
GlaxoSmithKline (GSK) has received additional approval for Imuran tablets, its proprietary immunosuppressant, from the Japanese Ministry of Health, Labor and Welfare.
Neurobiological Technologies, Inc. today announced it has received $4 million from Celtic Pharmaceutical Holdings L.P. (Celtic Pharma) as part of Neurobiological Technologies' previously announced sale of worldwide rights to Celtic Pharma for Xerecept, a Phase III clinical compound for the treatment of peritumoral brain edema.
The clinical trial market in Asia is poised to grow at an annual rate of at least 20 percent over the next five years, according to a forecast by logistics company TNT.
PRA International, a leading global clinical research organization, today announced a definitive agreement to acquire Pharma Bio-Research (PBR), a private early- phase clinical development company based in Zuidlaren, The Netherlands.
Swiss pharmaceutical company Actelion Ltd Monday said a study of its brain artery drug clazosentan showed that more time is needed to determine whether the product is effective, in a major setback that sent the shares sharply lower.
Novartis Pharma has obtained additional approval for Neoral (cyclosporine), its proprietary immunosuppressant, from the Ministry of Health, Labor and Welfare.